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Galectin–3 Is Associated With Stage B Metabolic Heart Disease and
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Background-—Obesity is a precursor to heart failure with preserved ejection fraction. Biomarkers that identify preclinical metabolic
heart disease (MHD) in young obese patients would help identify high-risk individuals for heart failure prevention strategies. We
assessed the predictive value of GAL3 (galectin–3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type
natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease.
Methods and Results-—Asymptomatic obese patients (n=250) and non-obese controls (n=21) underwent echocardiographic
cardiac phenotyping. Obese patients were classified as MHD positive (MHD-POS; n=94) if they had abnormal diastolic function or
left ventricular hypertrophy and had estimated pulmonary artery systolic pressure ≥35 mm Hg. Obese patients without such
abnormalities were classified as MHD negative (MHD-NEG; n=52). Serum biomarkers timed with echocardiography. MHD-POS and
MHD-NEG individuals were similarly obese, but MHD-POS patients were older, with more diabetes mellitus and metabolic
syndrome. Right ventricular coupling was worse in MHD-POS patients (P<0.001). GAL3 levels were higher in MHD-POS versus
MHD-NEG patients (7.72.3 versus 6.31.9 ng/mL, respectively; P<0.001). Both GAL3 and FSTL3 levels correlated with diastolic
dysfunction and increased pulmonary artery systolic pressure but not with left ventricular mass. In multivariate models including all
3 biomarkers, only GAL3 remained associated with MHD (odds ratio: 1.30; 95% CI, 1.01–1.68; P=0.04).
Conclusions-—In young obese individuals without known cardiovascular disease, GAL3 is associated with the presence of
preclinical MHD. GAL3 may be useful in screening for preclinical MHD and identifying individuals with increased risk of progression
to obesity-related heart failure with preserved ejection fraction. ( J Am Heart Assoc. 2019;8:e011100. DOI: 10.1161/JAHA.118.
011100.)
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M etabolic heart disease (MHD), a cardiomyopathycharacterized by left ventricular hypertrophy (LVH)
and/or diastolic dysfunction in the setting of preserved
ejection fraction, is common in young obese individuals, with
a prevalence ranging from 15% to 56%.1 The high frequency of
MHD in this population is noteworthy for 2 main reasons.
First, the prevalence of obesity is steadily rising in the United
States, with current estimates at 40% in 2014.2 Second,
obesity and metabolic syndrome are important precursors to
heart failure with preserved ejection fraction (HFpEF), a major
public health concern burdening our healthcare system with
significant morbidity, mortality, and cost.3,4
Heart failure (HF) is a progressive disorder, classified by
the American College of Cardiology/American Heart Associ-
ation (ACC/AHA) into 4 stages (A, B, C or D); stage B
represents structural heart disease in the absence of clinical
signs or symptoms of HF.5 Diastolic dysfunction, LVH,
and pulmonary hypertension (PH) are preclinical
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echocardiographic abnormalities that precede clinical HF in
individuals with stage B MHD.6–8 However, given the magni-
tude of the population at risk for MHD, the widespread use of
echocardiography as a screening tool is neither practical nor
cost effective. Inexpensive and convenient screening mea-
sures that can identify and mechanistically link to stage B
MHD would help prioritize and monitor high-risk individuals for
further assessment and early intervention.9
BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal
pro-B-type natriuretic peptide) are biomarkers that are useful in
the identification of stage B HF.10 However, both BNP and NT-
proBNP levels are depressed in obesity11 and tend to be lower
in HFpEF12,13 compared with HF with reduced ejection fraction,
thus severely limiting their utility in this population. FSTL3
(follistatin-like 3 peptide), similar to natriuretic peptides, is a
cardiomyokine that is upregulated by hypertrophic stimuli14
with increased circulating levels in HF with reduced ejection
fraction.15 Although FSTL3 has not been evaluated in HF and
obesity, it may provide an alternative to natriuretic peptides in
this setting. GAL3 (galectin–3) is elevated in symptomatic
patients with HF with reduced ejection fraction or HFpEF,16 but
little is known about its ability to identify preclinical stage B HF
of any etiology or to identify MHD in the setting of obesity.
Accordingly, our goal was to determine whether NT-proBNP,
FSTL3, or GAL3 was associated with preclinical MHD in obese
participants. Stage B MHD was specifically defined as (1) the
presence of increased left ventricular (LV) mass and/or
diastolic dysfunction function that is (2) accompanied by PH,
as elevated pulmonary pressure is a well-established prognos-
ticator and often portends hemodynamically important LV
disease.6,17,18
Methods
The data that support the findings of this study are available
from the corresponding author (D.M.G.) on reasonable
request.
Study Population
Patients with obesity (n=250) were recruited from outpatient
clinics at Boston Medical Center. Obesity was defined as a
body mass index (BMI; calculated as kg/m2) ≥30. Nonobese
volunteer controls with BMI <30 and no major comorbidities
(n=44) were also recruited from Boston Medical Center. All
participants with clinically recognized cardiovascular disease
(HF, PH, coronary artery disease, valvular disease, angina, or
atrial fibrillation), incidental asymptomatic LV systolic dys-
function (LV ejection fraction <50% on echocardiogram), or
significant pulmonary disease were excluded. Of the 250
obese patients, 19 were excluded for missing or inadequate
echocardiographic data (for the primary analysis), leaving
231 evaluable participants. Of the 44 control participants,
23 with evidence of asymptomatic echocardiographic abnor-
malities (incident valvular disease, diastolic abnormalities,
LVH, or PH) or missing data were excluded from the
analysis.
Categorization of MHD Disease
Primary analysis
For the primary analysis, MHD status classification of obese
participants was based on the presence or absence of
diastolic dysfunction, LVH, and PH. To be classified as MHD
positive (MHD-POS), a participant needed (1) to have
diastolic dysfunction or LVH and (2) to have PH. Obese
participants without diastolic dysfunction, LVH, or PH were
classified as MHD negative (MHD-NEG). Obese participants
with PH, LVH, and/or diastolic dysfunction but not meeting
criteria for MHD-POS were classified as indeterminate. Of
the 231 evaluable obese participants, 94 classified as
MHD-POS, 52 as MHD-NEG, and 85 as indeterminate
(Figure 1A).
Diastolic dysfunction was classified using the updated
2016 American Society of Echocardiography (ASE) guidelines
on evaluation of LV diastolic dysfunction.19 Because of the
high percentage of incomplete or absent tricuspid regurgita-
tion jets in this cohort, tricuspid regurgitation velocity was
replaced by pulmonary artery systolic pressure (PASP) calcu-
lated from pulmonary artery acceleration time (PAAT) using a
value of ≥31 mm Hg—a value equivalent to the tricuspid
regurgitation velocity requirement in the ASE criteria. LVH was
classified as present if the LV mass (indexed to height2.7) was
≥45 g/m2.7 in women and ≥49 g/m2.7 for men.20 PH was
Clinical Perspective
What Is New?
• Obesity is a precursor to heart failure with preserved
ejection fraction; metabolic heart disease, a cardiomyopathy
characterized by left ventricular hypertrophy and/or dias-
tolic dysfunction, is common in young obese individuals.
• In this study, GAL3 (galectin–3) independently associated
with metabolic heart disease, subclinical stage B heart
failure enriched with pulmonary hypertension, in young
obese individuals.
What Are the Clinical Implications?
• This study suggests biomarkers may help us identify preclin-
ical heart failure and asymptomatic pulmonary hypertension
in high-risk individuals with obesity and could serve as a
screening biomarker to initiate preventative strategies for
heart failure with preserved ejection fraction, including
echocardiographic screening and therapy initiation.
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classified as present if the estimated PASP derived from PAAT
was ≥35 mm Hg.17
Secondary analysis
In a secondary analysis, obese participants were classified as
PH-POS if the estimated PASP derived from PAAT was
≥35 mm Hg and as PH-NEG if PASP was <35 mm Hg. For
this analysis, 18 patients were excluded for inadequate quality
of the pulse-wave Doppler signal from the right ventricular
(RV) outflow tract, leaving 232 evaluable participants (93%) for
analysis.
Clinical Assessment
A comprehensive medical history and physical examination
were performed for all participants. Fasting laboratory values,
resting heart rate, blood pressure (obtained after 10 minutes





















43 with PH but no LVH/diastolic dysfunction




Obese individuals with poor quality or 
missing data for PAAT (n=18)
n=232
Stage B MHD PH-NEG 
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Figure 1. Flow diagram of the classification system of stage B MHD. A, Primary analysis used presence of
diastolic dysfunction, LVH, and PH for classification of MHD. B, Secondary analysis used PH as the sole
criterion for MHD presence. BUMETS indicates Boston University Metabolic Heart Disease Study; LVH, left
ventricular hypertrophy; MHD, metabolic heart disease; MHD-NEG, metabolic heart disease–negative; MHD-
POS, metabolic heart disease–positive; PAAT, pulmonary artery acceleration time; PASP, pulmonary artery
systolic pressure; PH, pulmonary hypertension.
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measurements), and anthropometrics were obtained for all
patients. Diabetes mellitus was defined as fasting blood
glucose level ≥126 mg/dL and/or active medical therapy
with an oral hypoglycemic agent and/or insulin. Hypertension
was defined as systolic blood pressure ≥140 mm Hg, dias-
tolic blood pressure ≥90 mm Hg, and/or current antihyper-
tensive therapy. Metabolic syndrome was defined as meeting
≥3 of the following 5 criteria: (1) increase waist circumference
(≥102 cm for men or ≥88 cm for women), (2) increased
fasting triglycerides (≥150 mg/dL), (3) high blood pressure
(≥130/85 mm Hg or antihypertensive therapy), (4) decreased
high-density lipoprotein cholesterol (<40 mg/dL in men,
<50 mg/dL in women), (5) impaired fasting glucose
(≥100 mg/dL).21 Ideal body weight was calculated using the
following equation: a+(2.3)([height in inches]60), where
a=50 kg for men and a=45.5 kg for women.22 The Boston
University Medical Center institutional review board approved
this study, and all participants provided informed consent
before study enrollment.
Assessment of Cardiac Structure and Function
Two-dimensional transthoracic echocardiograms using a 1- to
5-MHz transducer and commercially available ultrasound
machine (iE33; Phillips Medical Systems) was used by a single
experienced sonographer (A.P.). Echocardiograms were inter-
preted offline in a blinded manner. Standard echocardiographic
analysis was applied according to published recommenda-
tions.23 LVmass was calculated utilizing the cubedmethodwith
an index applying height to the power of 2.7 to account for body
habitus in our obese cohort.24 LV diastolic function included
pulse-wave Doppler assessment of early (E) and late (A)
transmitral inflow velocities, E/A ratio, E-wave deceleration
time, and tissue Doppler imaging of myocardial velocities
averaging both themedial and lateral mitral annulus.19 LV filling
pressure estimation, utilizing the mitral E wave and tissue
Doppler mean e0 velocity as a ratio, was calculated as described
previously.19
Right heart assessment was performed according to
published recommendations for right atrial area and RV basal
diameter.25 Tricuspid annular plane systolic excursion (TAPSE)
was obtained by placing an M-mode cursor on the lateral
tricuspid annulus in an apical 4-chamber view and capturing
maximal annular movement during systole. Utilizing pulse-
wave Doppler interrogation of the pulmonary artery ejection,
PAAT was measured as the time interval from the onset to
peak flow velocity of pulmonary artery flow. RV ejection was
the total time interval from onset to the cessation of
pulmonary artery flow. PASPs were estimated from PAAT
using a previously validated equation: 10([0.0049PAAT]+2.1).26
All echocardiographic measurements were averaged
over 3 consecutive cardiac cycles (when available).
Echocardiographic measurements were performed by 2
trained cardiologists (D.M.G. and Y.W.) with repeated mea-
surements of 10 scans showing an intraobserver coefficient of
variation of 1.6% to 6.1% and an interobserver coefficient of
variation of 1.8% to 7.0% for linear measurements. The
intraobserver coefficient of variation was 7.3% with intraclass
correlation coefficients ranging from 92% to 96%.
Biochemical Measurements
Following an overnight fast, blood samples were obtained from
study participants the next morning. The citrated plasma
samples were centrifuged immediately and stored at 80°C
until assayed. No freeze–thaw cycles were performed before
the assays described below. NT-proBNP, GAL3, and FSTL3
levels were determined using ELISA kits. Assay calibration was
performed according to the manufacturer’s recommendations,
with values normalized to a standard curve. Other biochemical
testing including total cholesterol, HDL (high-density
lipoprotein), triglyceride, and creatinine concentrations were
determined using standard clinical laboratory methods at
Boston Medical Center. Estimated glomerular filtration rate
(eGFR) was determined by the Chronic Kidney Disease
Epidemiology Collaboration formula: eGFR (mL/min/1.73m2)
=1419min (serum creatinine/j,1)a9max (serum creatinine/
j,1)1.20990.993Age91.018 (if female)91.159 (if black); j is
0.7 (females) and 0.9 (males) and a is 0.329 (females) and
0.411 (males).27
Statistical Analysis
Baseline characteristics and echocardiographic data were
reported as meanSD, median (interquartile range), or
number (percentage) unless otherwise specified. Between-
group differences were compared using 1-way ANOVA,
Kruskal–Wallis, or v2 analysis with Bonferroni correction
for multiple-comparison testing (P values considered statis-
tically significant at <0.05/3=0.02) for between-group
comparisons. Natural logarithm transformations were applied
to FSTL3 and NT-proBNP levels for analyses to normalize
right-skewed distributions. Correlation testing for biomarkers
and echocardiographic and clinical characteristics used
pairwise Pearson correlation coefficients. Multivariate linear
regression models were used to explore relationships
between echocardiographic parameters and clinical charac-
teristics. Univariate logistic regression models using MHD-
POS as the outcome of interest were applied to clinical and
echocardiographic variables to determine associations. Vari-
ables that were significant (P<0.01) were subsequently
applied in fully adjusted multivariate models to prevent
model overfitting. All analyses were performed using SAS
9.3 (SAS Institute).
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MHD-POS and MHD-NEG participants were similar in body
weight, BMI, and body surface area, with 40% of all obese
patients qualifying for class 3 obesity with a BMI ≥40
(Table 1). Control participants had a mean BMI of 25 with
no diabetes mellitus, hypertension, or metabolic syn-
drome. MHD-POS participants were older with a higher
prevalence of comorbidities including diabetes mellitus,
hypertension, hyperlipidemia, and metabolic syndrome
than MHD-NEG participants. Likewise, MHD-POS (versus
MHD-NEG) participants were more likely to be receiving
Table 1. Baseline Characteristics
Nonobese Controls (n=21) Obese MHD-NEG (n=52) Obese MHD-POS (n=94) P Value
Age, y 4312 3611 479* <0.001
Female, n (%) 18 (86) 47 (90) 69 (73) 0.04
Black, n (%) 9 (43) 34 (65) 61 (65) 0.15
Anthropometrics
Height, m 1676 1669 16610 0.70
Ideal body weight, kg 606 588 599 0.68
Actual body weight, kg 698 10322† 10922† <0.001
Body mass index, kg/m2 253 377† 408† <0.001
Body surface area, m2 1.80.1 2.10.2† 2.10.2† <0.001
Waist circumference, cm 829 11318† 11916† <0.001
Comorbidities, n (%)
Diabetes mellitus 0 (0) 6 (12) 37 (39) <0.001
Hypertension 0 (0) 16 (31) 60 (64) <0.001
Current smoking 1 (4) 4 (8) 13 (14) 0.45
Obstructive sleep apnea 0 (0) 6 (12) 20 (21) 0.02
Hyperlipidemia 1 (5) 14 (27) 50 (53) <0.001
Metabolic syndrome 0 (0) 28 (54) 79 (84) <0.001
Medications, n (%)
ACEI or ARB 0 (0) 8 (15) 43 (46) <0.001
b-Blocker 0 (0) 4 (8) 23 (24) 0.002
Oral hypoglycemic agent 0 (0) 6 (12) 26 (28) 0.002
Insulin 0 (0) 1 (2) 15 (16) 0.007
Laboratory values
Total cholesterol, mg/dL 184 (178–217) 182 (157–210) 188 (165–206) 0.85
HDL, mg/dL 61 (52–67) 45 (39–53)† 45 (39–53)† <0.001
Triglycerides, mg/dL 60 (48–84) 100 (70–151) 117 (82–176)† 0.008
Triglyceride/HDL ratio 1.1 (0.7–1.6) 2.5 (1.3–3.3) 2.7 (1.8–4.0)† 0.001
eGFR, mL/min/1.73 m2 9916 12825† 12228† <0.001
Biomarkers
NT-proBNP, pmol/L 420 (279–736) 554 (431–684) 607 (485–773) 0.36
GAL3, ng/mL 5.71.6 6.31.9 7.72.3*† <0.001
FSTL3, pg/mL 4665 (3976–5951) 5335 (4414–6970) 5768 (4477–7521) 0.02
Data are meanSD, median (interquartile range), or n (%). P value reflect overall group differences. P value listed reflects ANOVA comparison across all 3 groups; symbols denote between
group comparisons with Bonferonni correction. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate;
FSTL3, follistatin-like 3 peptide; GAL3, galectin–3; HDL, high-density lipoprotein; MHD-NEG, metabolic heart disease–negative; MHD-POS, metabolic heart disease–positive; NT-proBNP,
N-terminal pro-B-type natriuretic peptide.
*P<0.02 vs obese MHD-NEG participants.
†P<0.02 vs controls.
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hypertensive therapy and hypoglycemic medications (oral
or insulin therapy). MHD-indeterminate participants, who
were excluded from the primary analysis (n=85), were
generally similar to MHD-POS and MHD-NEG participants
regarding comorbidities and echocardiographic variables
(Table S1).
Cardiac Structure and Function
As expected given the grouping criteria, MHD-POS (versus
MHD-NEG) participants had higher LV mass and higher mean
PASP (489 versus 274 mm Hg, respectively; Table 2). In
addition, MHD-POS individuals had more LV concentric
remodeling. MHD-POS participants had worse diastolic
function, with increased A waves, lower E/A ratios, and
increased left atrial size indexes.
Biomarkers
Relationship to clinical characteristics
Whereas NT-proBNP and FSTL3 were not different among the
3 groups, GAL3 was higher in MHD-POS participants than in
controls or MHD-NEG individuals (Table 1). Among all MHD
participants, GAL3 correlated with age (q=0.34, P<0.001),
eGFR (q=0.32, P<0.001), and diabetes mellitus (q=0.23,
P=0.007) but not with height, weight, BMI, or hypertension (all
P>0.05). FSTL3 correlated with age (q=0.35, P<0.001),
weight (q=0.27, P=0.002), BMI (q=0.17, P=0.05),
Table 2. Cardiac Structure and Function
Nonobese Controls (n=21) Obese MHD-NEG (n=52) Obese MHD-POS (n=94) P Value
Left heart parameters
LV diastolic dimension, mm 454 464 465 0.54
LVEDV, mL 72 (61–80) 79 (68–93) 86 (71–104)* 0.01
LVEDV index, mL/m2 409 4010 4110 0.61
LVM, g 11224 14231* 17348*† <0.001
LVM index, g/m2.7 286 366* 4412*† <0.001
LVM/LVEDV, g/mL 1.60.3 1.80.4 2.00.5*† <0.001
Relative wall thickness 0.40.1 0.40.1 0.50.1*† <0.001
LVEF, % 646 656 647 0.56
Mitral E wave, cm/s 7013 8317 7819 0.03
Mitral A wave, cm/s 5315 5814 7113*† <0.001
Mitral E/A ratio 1.40.4 1.50.4 1.10.3*† <0.001
Mean e0 wave, cm/s 122 112 92*† <0.001
E/e0 ratio 61 82 93*† <0.001
Left atrial diameter, mm 314 365* 385* <0.001
LAV index (BSA), mL/m2 3211 298 349* 0.003
LAV index (height), mL/height2.7 145 154 195*† <0.001
Right heart parameters
RV basal diameter, mm 365 365 395 0.01
TAPSE, mm 234 233 234 0.97
Right atrial area, cm2 143 143 174† <0.001
PAAT, ms 18129 16814 10619*† <0.001
PASP, mm Hg 256 274 489*† <0.001
TAPSE/PASP (mm/mm Hg) 1.0 (0.7–1.2) 0.8 (0.8–1.0)* 0.5 (0.4–0.6)*† <0.001
Data are meanSD, median (interquartile range), or n (%). P values reflect overall group differences with ANOVA comparison across all 3 groups; symbol denotes between-group
comparisons with Bonferonni adjustment. BSA indicates body surface area; LAV, Left atrial volume; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular
ejection fraction; LVM, left ventricular mass; MHD-NEG, metabolic heart disease–negative; MHD-POS, metabolic heart disease–positive; PAAT, pulmonary artery acceleration time; PASP,
pulmonary artery systolic pressure; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion.
*P<0.02 vs controls.
†P<0.02 vs obese MHD-NEG participants.
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hypertension (q=0.29, P<0.001), diabetes mellitus (q=0.25,
P=0.004), and eGFR (q=0.24, P=0.006). In contrast, NT-
proBNP did not correlate with any clinical characteristic in the
MHD-POS or MHD-NEG participants, including hypertension,
diabetes mellitus, eGFR, and BMI.
Relationship to cardiac structure and function
Among the MHD participants, both GAL3 and FSTL3 corre-
lated with measures of LV diastolic function (mean e0 velocity,
E/A ratio, and E/e0 ratio), PASP, and the TAPSE/PASP ratio
but did not correlate with LV volume or mass (Table 3 and
Figure 2). By comparison, NT-proBNP did not correlate with
mean e0 velocity, E/e0 ratio, or LV mass or volume and
correlated only with E/A.
Cardiac Structure and Function and Pulmonary
Hemodynamics in MHD
LVH and diastolic function
Of the MHD-POS participants, 7% had isolated LVH, 59% had
isolated abnormal diastolic function, and 34% had both LVH
and diastolic dysfunction. Among these MHD-POS partici-
pants, BMI was strongly correlated to LV mass indexed to
height2.7 (q=0.52, P<0.001) but not with mean e0 (q=0.17,
P=0.10). Among the MHD-POS participants, 38% had con-
centric remodeling, 30% had concentric hypertrophy, and 12%
had eccentric hypertrophy.
Pulmonary hypertension
Among all obese participants (both MHD-POS and MHD-NEG),
PASP correlated with several measures of abnormal diastolic
function including increased left atrial volume index (q=0.24,
P=0.004), decreased mitral E/A ratio (q=0.37, P<0.001),
increased E/e0 (q=0.33, P<0.001), and decreased mean e0
(q=0.46, P<0.001; Figure 3A). In addition, PASP correlated
with increases in LV mass/volume ratio (q=0.27, P=0.001)
and LV mass indexed to height2.7 (q=0.35, P<0.001;
Figure 3B). In multivariate linear regression models with
clinical variables, age (P=0.01), waist circumference (P=0.01),
and diabetes mellitus (0.03) all associated with PASP. Mean e0
(P=0.002), E/A ratio (P=0.02), left atrial volume index
(P=0.002), and LV mass indexed to height2.7 (P=0.009) were
all independently predictive of PASP in echocardiographic
multivariate models.
RV uncoupling
Although TAPSE was similar across the 3 groups (Table 2),
elevation of PASP in the MHD-POS group was associated with
a decrease in the TAPSE/PASP ratio suggestive of early right
ventricle–pulmonary artery uncoupling (Figure 4A). Mean e0
was correlated with TAPSE/PASP (q=0.51, P<0.001; Fig-
ure 4B) and remained significant after adjustment for age,
sex, LV ejection fraction, and LV mass indexed to height2.7
(P=0.001), suggesting a relationship between RV uncoupling
and diastolic dysfunction.
Table 3. Echocardiographic Correlates With Biomarkers in
Obese Participants
Biomarker Variable q P Value
GAL3 Diastolic function
Mean e0 0.30 <0.001
Mitral E/A ratio 0.27 0.002
E/e0 0.30 <0.001
LAV indexed to BSA 0.04 0.68
LV remodeling
LVM indexed to height2.7 0.05 0.56




TAPSE/PASP ratio 0.30 0.002
FSTL3 Diastolic function
Mean e0 0.35 <0.001
Mitral E/A ratio 0.34 <0.001
E/e0 0.31 <0.001
LAV indexed to BSA 0.21 0.02
LV remodeling
LVM indexed to height2.7 0.04 0.67




TAPSE/PASP ratio 0.24 0.02
NT-proBNP Diastolic function
Mean e0 0.08 0.40
Mitral E/A ratio 0.20 0.03
E/e0 0.08 0.42
LAV indexed to BSA 0.05 0.59
LV remodeling
LVM indexed to height2.7 0.05 0.59




TAPSE/PASP ratio 0.18 0.08
BSA indicates body surface area; FSTL3 indicates follistatin-like 3 peptide; GAL3, galectin–
3; LAV, left atrial volume; LV, left ventricular; LVEDV, left ventricular end-diastolic volume;
LVM, left ventricular mass; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PASP,
pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion.
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Correlation  of  galectin–3, follistatin-like 3, and NT-proBNP and mean e’
A
Rho -0.30, p < 0.001 Rho -0.35, p < 0.001 Rho -0.08, p = 0.40
Correlation  of  galectin–3, follistatin-like 3, and NT-proBNP and LV mass
B
Rho -0.05, p=0.56 Rho 0.04, p=0.67 Rho 0.05, p=0.59
Correlation  of  galectin–3, follistatin-like 3, and NT-proBNP and PASP
C
Rho 0.33, p<0.001 Rho 0.21, p=0.02 Rho 0.11, p=0.25
Obese Stage B MHD-NEG
Obese Stage B MHD-POS
Figure 2. Correlations of biomarkers GAL3 (galectin–3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-
type natriuretic peptide) with diastolic function, LV mass, and pulmonary pressures. A, Biomarker correlations with mean e0
velocity. B, Biomarker correlations with LV mass indexed to height.2.7 C, Biomarker correlations with PASP. LV indicates left
ventricular; MHD-NEG, metabolic heart disease–negative; MHD-POS, metabolic heart disease–positive; PASP, pulmonary artery
systolic pressure.
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Primary Analysis: Clinical and Biomarker
Correlates of MHD
Significant univariate clinical correlates of MHD-POS individ-
uals included age, female sex, hypertension, diabetes mellitus,
waist circumference, and hyperlipidemia (Table S2). Among
the 3 candidate biomarkers, GAL3 was associated with MHD-
POS individuals in univariate analysis, whereas FSTL3 and NT-
proBNP were not. In age- and sex-adjusted multivariate
logistic regression models (Table 4), GAL3 was the only
biomarker that remained associated with MHD-POS partici-
pants (odds ratio: 1.30; 95% CI, 1.01–1.68; P=0.04).
Rho -0.46, p < 0.001
A
Obese Stage B MHD-NEG
Obese Stage B MHD-POS
Obese Stage B MHD-NEG
Obese Stage B MHD-POS
Rho 0.35, p < 0.001
B
Figure 3. Relationship of left-sided cardiac disease and pulmonary pressures in obese participants. A,
Correlation of mean e0 velocity and PASP. B, Correlation of LV mass indexed to height2.7 and PASP. LV
indicates left ventricular; MHD-NEG, metabolic heart disease–negative; MHD-POS, metabolic heart disease–
positive; PASP, pulmonary artery systolic pressure.
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Secondary Analysis: Clinical and Biomarker
Predictors of PH Presence
In a secondary analysis, obese participants were classified as
PH-POS solely on the basis of PASP ≥35 mm Hg or PH-NEG
if PASP was <35 mm Hg (Figure 1B). This criterion identified
138 obese PH-POS participants and 94 PH-NEG participants
(Tables S3 and S4). In the PH-POS individuals, (1) PASP
correlated with mean e0 (q=0.30, P<0.001; Figure S1A), (2)
PASP correlated with LV mass indexed to height2.7
(q=0.17, P=0.01), and (3) mean e0 correlated with the
TAPSE/PASP ratio (q=0.33, P<0.001; Figure S1B). Similar
univariate predictors of MHD PH-POS individuals were noted,
as seen in the former analysis (Table S5). As in the primary
analysis, multivariate models with age and sex adjustment
showed that only GAL3 was associated with PH-POS





Obese Stage B MHD-NEG
Obese Stage B MHD-POS
Rho 0.51, p < 0.001
Figure 4. RV mechanics in stage B metabolic heart disease. A, Uncoupling of RV and pulmonary
circulation in stage B metabolic heart disease. B, Relationship of LV diastolic function on RV mechanics
in obese participants. LV indicates left ventricular; MHD, metabolic heart disease; MHD-NEG, metabolic
heart disease–negative; MHD-POS, metabolic heart disease–positive; PASP, pulmonary artery systolic
pressure; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion.
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Discussion
The goal of this study was to determine whether biomarkers
can be used for the early identification of preclinical (ie, ACC/
AHA stage B) HF in a cohort of asymptomatic young obese
participants. For the purpose of this analysis, stage B MHD
was defined by the presence of increased LV mass and/or
diastolic dysfunction that was accompanied by PH. There
were 2 major findings. First, of the 3 biomarkers tested, we
found that only GAL3 independently identified stage B MHD in
otherwise asymptomatic young obese participants. Second,
we found that in young obese participants, resting PH (1) is
common, occurring in 59% participants; (2) correlates strongly
with LV diastolic dysfunction and LVH; (3) correlates with RV
uncoupling (lower TAPSE/PASP ratio); and (4) correlates with
GAL3.
Classification of Stage B MHD Using LVH,
Diastolic Dysfunction, and PH
Obesity is associated with an increased risk of incident HF,3,4
and mounting evidence suggests that among patients with
HFpEF, there is a distinct “metabolic” phenotype with obesity,
type 2 diabetes mellitus, and/or metabolic syndrome.28
Obesity has been linked with subclinical alterations in cardiac
structure (LVH) and function (diastolic dysfunction), which are
generally viewed as cardiac hallmarks of MHD.29,30 These
structural and functional alterations are common in patients
with obesity and may remain asymptomatic for extended
periods. Importantly, LVH and diastolic dysfunction are impor-
tant drivers in the progression to clinical HF, particularly
HFpEF.31 A recent meta-analysis that polled 7564 participants
from 5 studies showed that asymptomatic diastolic dysfunction
contributed to a 70% higher risk of progressing to clinical HF
compared with participants without diastolic dysfunction.32
For this study, we defined MHD as the presence of
diastolic dysfunction and/or LVH in the presence of PH.
Diastolic dysfunction alone was prevalent in 59% of the MHD-
POS individuals in our study. As expected, in these partici-
pants, the A wave was increased, the E/A ratio was
decreased, and the left atrium was larger. LVH was present
in 7% of MHD-POS participants; both entities, diastolic
dysfunction and LVH, were present in 34%. The prevalence
of LVH in our study (41%) is consistent with many prior
observations, including a recent meta-analysis of 22 studies in
which the average prevalence of LVH in obese participants
was 56% (range: 20–85%).1 As expected, LVH correlated with
diastolic dysfunction, but as we33 and others34 have noted,
there are many patients in whom diastolic dysfunction is not
associated with LVH.
A novel key aspect of this study is the inclusion of PH, in
addition to LVH and/or diastolic dysfunction, in the identifica-
tion of patients with MHD. The functionally important conse-
quence of impaired LV relaxation and/or filling is an elevation in
pulmonary artery pressures, which plays a pathophysiologic
role in HFpEF patients.17 PH is a major determinant of clinical
symptoms and outcomes in patients with symptomatic
HFpEF.35 An inherent limitation of using diastolic relaxation
and/or LVH to define MHD is that both measures are only
indirectly related to PH. PASP was determined using PAAT, an
approach that allowed pulmonary artery pressure to be
estimated in >90% of patients in this study. Participants were
deemed to have MHD only if diastolic dysfunction and/or LVH
were associated with PH, which was defined as a resting PASP
≥35 mm Hg. Of the 250 obese participants in this study with
analyzable echocardiographic data, 59% had LVH or diastolic
dysfunction. With the additional requirement for PH, the
number of obese participants classified as MHD-POS
decreased to 94 patients (38% of obese individuals included
in the primary analysis). PASP correlated significantly with
mean e0 (q=0.46) and LV mass (q=0.35), indicating that LV
disease was a major determinant of the elevated pulmonary
pressures noted in the obese cohort. The goal of this added
criterion was to increase the specificity of the definition of
MHD. As discussed later, the use of PH alone as the definition
of MHD for a secondary analysis was also robust, likely
reflecting the ability of PH to provide an integrated measure of
the hemodynamic severity of left-sided dysfunction.
Table 4. Logistic Regression Analysis for Presence of Obese
Stage B MHD Phenotype
OR (95% CI) P Value
GAL3
Model 1: Age and sex 1.28 (1.03–1.59) 0.004
Model 2: Clinical risk model 1.24 (1.01–1.53) 0.05




Model 1: Age and sex 0.71 (0.57–1.36) 0.56
Model 2: Clinical risk model 0.84 (0.53–1.35) 0.47




Model 1: Age and sex 1.39 (0.85–2.28) 0.19
Model 2: Clinical risk model 1.32 (0.83–2.11) 0.24
Model 3: Model 1+GAL3+FSTL3* 1.49 (0.89–2.49) 0.13
Clinical risk model: history of hypertension, diabetes mellitus, hyperlipidemia, waist
circumference, and estimated glomerular filtration rate in addition to biomarker of
interest. FSTL3 indicates follistatin-like 3 peptide; GAL3, galectin–3; MHD, metabolic
heart disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio.
*FSTL3 and NT-proBNP were log-transformed in regression models for data
normalization. OR for both biomarkers reflect 1-SD increase in log-transformed
biomarker.
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NT-proBNP Fails to Associate With MHD
Natriuretic peptides are well-established biomarkers for
prognosis in HF patients.10 However, on the order of 30%
of patients with established HFpEF—most notably, those
who are younger and/or obese—have normal BNP levels,36
likely related to the observation that obesity and metabolic
disease are associated with lower circulating natriuretic
peptides.37 Conversely, natriuretic peptides are useful
screening biomarkers for the detection of patients at risk
for HF. In STOP-HF (Natriuretic Peptide-Based Screening and
Collaborative Care for HF) and PONTIAC (NT-proBNP
Selected Prevention of Cardiac Events in a Population of
Diabetic Patients Without a History of Cardiac Disease),
natriuretic levels were used to randomize stage A patients to
intensive therapy, which led to decreased rates of incident
HF and hospitalization. Although the recruitment of these
cohorts did not specifically target obesity or metabolic
syndrome, the average BMIs suggested that enrollees, on
average, were overweight (STOP-HF) or had class 1 obesity
(PONTIAC).38,39 Therefore, it seemed possible that NT-
proBNP could be useful for the identification of stage B HF
in our young obese population.
In our cohort, however, NT-proBNP proved to be an
ineffective biomarker for detection of stage B HF due to MHD.
There were no differences in NT-proBNP levels between MHD-
POS and MHD-NEG individuals and no significant associations
with clinical characteristics (eg, hypertension, diabetes melli-
tus, eGFR, and BMI) or measures of cardiac structure (ie, LVH,
LV volume, RV parameters),mostmeasures of diastolic function
(mean e0, LA size, E/e0 ratio), or PH. The failure of NT-proBNP to
identify stage B MHD likely relates to confounding factors that
suppress circulating natriuretic levels in the setting of obe-
sity.37
FSTL3 Correlates to Metabolic Disease But Not
MHD
FSTL3, like natriuretic peptides, is a cardiac myokine. FSTL3
appears to play a role in the regulation of myocyte growth and
mediates paracrine activation of fibroblasts in the heart.40 FSTL
gene expression increases in myocardium from patients with
severe HF undergoing therapy with an LV assist device.15
FSTL3 also has a role in metabolic regulation; levels are
increased in obesity,41 and deletion in mice leads to favorable
visceral fat and glucose homeostasis.42 Because the levels of
FSTL3 are increased in HF and there is no apparent suppression
of levels in obesity, we reasoned that FSTL3 might be a useful
biomarker for stage B MHD in obese individuals. Interestingly,
in our population, plasma FSLT3 levels were higher in obese
participants, particularly in those with MHD, and correlated
significantly with diastolic indexes (mean e0, E/A ratio, E/e0
ratio) and higher PASP but not with LVH. However, in univariate
and fully adjusted multivariate models, FSTL3 was not able to
identify MHD among obese patients, suggesting that in these
patients FSTL3 may reflect the abnormal metabolic milieu
rather than the cardiac phenotype.
GAL3 Is Associated With MHD
A major finding of this study is that GAL3 is associated with
stage B HF due to MHD in young obese individuals, and in
particular, GAL3 links strongly to diastolic dysfunction and
PH. In contrast to FSTL3, this association persisted with
multivariable adjustments including age, sex, and clinical risk
factors (hypertension, diabetes mellitus, hyperlipidemia, waist
circumference, and eGFR). Prior studies have shown that
plasma GAL3 levels are increased in both HFpEF patients and
those with HF with reduced ejection fraction.43 In stage C
HFpEF individuals, GAL3 is associated with poor outcomes.44
Likewise, GAL3 predicted incident HF in multivariate models
in the Framingham Heart Study.45 Ours is the first study to
test the role of GAL3 in predicting a preclinical HF phenotype
in asymptomatic young obese individuals at high risk of HF
development.
The mechanism responsible for elevated GAL3 in our
participants likely relates to the underlying myocardial process.
GAL3, a b-galactoside binding lectin derived from macro-
phages, promotes cardiac fibroblast proliferation, collagen
production, and inflammation and is associated with LV
dysfunction.46 In mice, the inhibition of GAL3 blocked myocar-
dial fibrosis, inflammation, and superoxide levels cause by a
high-fat diet, suggesting that GAL3 may play pathophysiologic
role in cardiac dysfunction with obesity.47 Because LV diastolic
dysfunction is a primary process in MHD, it is likely that GAL3 in
some way reflects the biology of that process.
GAL3 Associates With PH
The measurement of PASP using PAAT allowed for several
important findings. First, it provided the novel demonstration
that GAL3 strongly associates with PH in these asymptomatic
participants. PH was surprisingly common, occurring in 59% of
the young asymptomatic obese participants in our study.
Although prior studies have not assessed PH in asymptomatic
young obese individuals, our findings are consistent with those
of Brittain et al, who found that PH was associated with insulin
resistance and diastolic dysfunction in a middle-aged popula-
tion.48 The implications of PH in our population are not clear;
however, PH is a powerful predictor of mortality in patients with
symptomatic HF35 and predicts HF admissions among black
patients.3 It is also noteworthy that among our participants, PH
was associated with early evidence of RV uncoupling, which
portends a worse prognosis in patients with HFpEF.49
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The source of the elevated GAL3 in our participants cannot
be completely determined from this study. PH correlated with
left heart disease in these individuals—in particular, diastolic
dysfunction and LVH—suggesting that PH may be secondary
to elevated left heart filling pressures. PH due to left heart
disease (World Health Organization group 2) is the most
frequent cause of PH worldwide. In addition, it is noteworthy
that in patients with pulmonary arterial hypertension, GAL3 is
associated with RV dysfunction,50 raising the possibility that
among our participants, elevated GAL3 may in part reflect
release from the lungs and/or the right ventricle in addition to
the left heart.
Limitations
Because this study was noninvasive, we did not have invasive
hemodynamics to exclude patients who may have had
elevated pulmonary pressures not related to left-sided disease
(occult pulmonary embolism, significant obstructive sleep
apnea, primary PH). However, with the mandatory inclusion of
left-sided cardiac disease, as reflected by LVH and/or
diastolic dysfunction, we attempted to identify individuals
who likely had PH due to left-sided disease; individuals with
any known pulmonary disease were excluded from the study.
The sample size was diminished given exclusion of patients
whose MHD status was indeterminate. However, the sec-
ondary analysis, which was based on the presence or absence
of PH and included all 232 evaluable patients, confirmed the
association of GAL3 with MHD.
Conclusions
We showed that stage B MHD and PH are common in
asymptomatic young individuals who are obese. GAL3 is
independently associated with MHD and PH in these high-
risk individuals, even among traditional risk factors, whereas
NT-proBNP and FSTL3 are not. The strong relationship
between PH and GAL3 raises the possibility that GAL3 is
involved in the pathophysiology of PH in metabolic disease
and/or that PH itself may lead to an increase in GAL3 levels.
GAL3 may be of value in identifying preclinical HF and/or PH
in obese individuals, a targetable group for preventative HF
interventions.
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Table S1. Baseline characteristics of persons removed from Stage B MHD primary 




All obese patients 





Age, y 40  11 43  11 0.09 
Female, n (%) 60 (71) 116 (79) 0.31 
Black, n (%) 48 (56) 95 (65) 0.37 
Body mass index, kg/m2 41  11 39  8 0.09 
Diabetes 31 (36) 43 (29) 0.27 
Hypertension 44 (52) 76 (52) 0.97 
Current smoking 13 (15) 17 (11) 0.43 
Obstructive sleep apnea 17 (20) 26 (18) 0.70 
Hyperlipidemia 34 (40) 64 (44) 0.57 
Metabolic syndrome 70 (82) 107 (73) 0.12 
HDL, mg/dL 43  10 46  11 0.03 
Triglycerides, mg/dL 134 (81-186) 111 (77-173) 0.34 
eGFR, mL/min/1.73m2 135  34 124  27 0.02 
NT-proBNP, pmol/L 562 (415-701) 574 (458-729) 0.69 
GAL3, ng/mL 7  2 7  2 0.21 
FSTL3, pg/mL 5417 (4514-6471) 5721 (4477-7101) 0.26 
LVM index, g/ht2.7 43  11 41  11 0.30 
LVM/LVEDV, g/mL 1.8 (1.6-2.2) 1.9 (1.6-2.2) 0.82 
LVEF, % 63  7 65  6 0.24 
Mitral E/A ratio 1.3  0.3 1.2  0.4 0.12 
Mean e’ wave, cm/s 10  2 10  3 0.09 
E/e’ ratio 8  2 9  3 0.05 
Left atrial volume index (BSA), mL/m2 32  10 33  9 0.81 
RV basal diameter, mm 38  5 38  5 0.34 
TAPSE, mm 24  4 23  3 0.31 
PA acceleration time, ms 132  34 128  35 0.28 
PA systolic pressure, mmHg 39  12 41  13 0.28 
TAPSE/PA systolic pressure 
(mm/mmHg) 
0.61 (0.47-0.77) 0.58 (0.45-0.77) 0.34 
 
Data are mean  SD, median (interquartile range), or n (%). P value between group comparisons.  
MHD = metabolic heart disease; LV, left ventricle; LVM, left ventricular mass; LVEF, left ventricular 
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Table S2. Logistic regression analysis of predictors of obese MHD phenotype. 
 
 OR (95% CI) P value 
Age 1.11 (1.07-1.15) <0.001 
Female sex 0.29 (0.11-0.82) 0.02 
Black 1.09 (0.68-1.75) 0.73 
Hypertension 3.97 (1.93-8.19) <0.001 
Diabetes 4.98 (1.93-12.81) <0.001 
BMI 1.05 (1.00-1.10) 0.06 
Waist circumference 1.03 (1.00-1.05) 0.03 
Hyperlipidemia 3.08 (1.48-6.43) 0.003 
eGFR 0.99 (0.98-1.00) 0.19 
GAL3 1.35 (1.13-1.62) 0.001 
FSTL3* 1.30 (0.91-1.85) 0.15 
NT-proBNP* 1.36 (0.88-2.09) 0.17 
 
BMI, body mass index; eGFR, estimated glomerular filtration rate; GAL3, galectin-3; FSTL3, follistatin-like 
3 peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide 
*FSTL3 and NT-proBNP were log-transformed in regression models for data normalization. OR for both 
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Age, y 43  12 40  11 43  11 0.05 
Female, n (%) 18 (86) 99 (84) 99 (72) 0.10 
Black, n (%) 9 (43) 58 (62) 86 (62) 0.03 
Anthropometrics 
Height, m 167  6 166  11 167  9 0.54 
Ideal body weight, kg 60  6 58  11 60  9 0.41 
Actual body weight, kg 72 (64-74) 105 (87-119)* 114 (96-127)* <0.001 
Body mass index, kg/m2 25 (22-26) 36 (32-43)* 39 (34-45)* <0.001 
Body surface area, m2 1.8  0.1 2.1  0.3* 2.2  0.3* <0.001 
Waist circumference, cm 81 (74-91) 117 (102-122) 121 (107=132)*† <0.001 
Comorbidities, n (%) 
Diabetes 0 (0) 18 (19) 56 (41) <0.001 
Hypertension 0 (0) 39 (41) 82 (59) <0.001 
Current smoking 1 (4) 10 (11) 20 (14) 0.02 
Obstructive sleep apnea 0 (0) 16 (17) 27 (20) 0.04 
Hyperlipidemia 1 (5) 29 (31) 69 (50) <0.001 
Metabolic syndrome 0 (0) 58 (62) 120 (87) <0.001 
Medications, n (%) 
ACEI or ARB 0 (0) 21 (22) 59 (43) <0.001 
-Blocker 0 (0) 17 (18) 28 (20) 0.03 
Oral hypoglycemic agent 0 (0) 15 (16) 40 (29) <0.001 
Insulin 0 (0) 5 (5) 18 (13) 0.04 
Laboratory values     
Total cholesterol, mg/dL 184 (178-217) 180 (154-207) 186 (163-203) 0.36 
HDL, mg/dL 61 (52-67) 44 (38-50)* 43 (38-50)* <0.001 
Triglycerides, mg/dL 60 (48-84) 104 (74-174) 126 (82-185)* 0.003 
Triglyceride/HDL ratio 1.1 (0.7-1.6) 2.5 (1.5-3.9)* 2.9 (1.9-4.3)* 0.002 
eGFR, mL/min/1.73m2 99 (16) 125  27* 131  33* <0.001 
Biomarkers 
NT-proBNP, pmol/L 420 (279-736) 554 (415-694) 589 (373-773) 0.58 
GAL3, ng/mL 5.7  1.6 6.4  2.0 7.4  2.2*† <0.001 








Data are mean  SD, median (interquartile range), or n (%). P value reflect overall group differences. 
MHD PH-NEG, metabolic heart disease pulmonary hypertension negative individuals; MHD PH-POS, 
metabolic heart disease pulmonary hypertension positive individuals; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; HDL, high-density lipoprotein; eGFR, estimated 
glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; GAL3, galectin-3; FSTL3, 
follistatin-like 3 peptide 
*P<0.02 versus controls 
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Left heart parameters 
LV diastolic dimension, mm 45  4 47  5 46  5 0.20 
LV end-diastolic volume, mL 72 (61-80) 82 (71-104) 86 (73-105)* 0.02 
LV end-diastolic volume index, 
mL/m2 
40  9 42  10 41  9 0.77 
LV mass, g 112  24 165  47* 166  45* <0.001 
LVM index, g/ht2.7 28  6 42  11* 41  11* <0.001 
LVM/LVEDV, g/mL 1.6 (1.37-1.83) 1.9 (1.6-2.2)* 1.9 (1.6-2.2)* 0.007 
LVEF, % 64  6 65  7 63  6 0.03 
Mitral E wave, cm/s 70  13 80  17 79  18 0.16 
Mitral A wave, cm/s 53  15 61  14* 68  13* 0.001 
Mitral E/A ratio 1.4  0.4 1.4  0.4 1.2  0.3*† <0.001 
Mean e’ wave, cm/s 12  2 11  2 9  2*† <0.001 
E/e’ ratio 6  1 8  2* 9  3*† <0.001 
Left atrial diameter, mm 31  4 38  5* 38  4* <0.001 
Left atrial volume index (BSA), 
mL/m2 
32  11 33  10 32  8 0.59 
Left atrial volume index (ht), 
mL/ht2.7 
14  5 18  7* 18  5 0.08 
Right heart parameters 
RV basal diameter, mm 36  5 38  5 38  5 0.56 
TAPSE, mm 23  4 23  4 23  4 0.78 
Right atrial area, cm2 14  3 15  3 16  3 0.06 
PA acceleration time, ms 181  29 164  20 106  18*† <0.001 
PA systolic pressure, mmHg 25  6 28  5 48  8*† <0.001 










Data are mean  SD, median (interquartile range), or n (%). P value reflect overall group differences. 
MHD PH-NEG, metabolic heart disease pulmonary hypertension negative individuals; MHD PH-POS, 
metabolic heart disease pulmonary hypertension positive individuals; LV, left ventricle; LVM, left 
ventricular mass; LVEF, left ventricular ejection fraction; BSA, body surface area; ht, height; RV, right 
ventricle; TAPSE, tricuspid annular plane systolic excursion; PA, pulmonary artery 
*P<0.02 versus controls 
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Table S5. Logistic regression analysis of predictors of obese Stage B MHD PH 
phenotype. 
 
 OR (95% CI) P value 
Age 1.03 (1.01-1.05) 0.02 
Female sex 0.52 (0.27-1.00) 0.05 
Black 0.99 (0.68-1.43) 0.94 
Hypertension 2.07 (1.21-3.52) 0.008 
Diabetes 2.89 (1.56-5.34) <0.001 
BMI 1.03 (1.00-1.06) 0.07 
Waist circumference 1.02 (1.01-1.04) 0.003 
Hyperlipidemia 2.24 (1.29-3.89) 0.004 
eGFR 1.01 (1.00-1.02) 0.12 
GAL3 1.26 (1.10-1.45) 0.001 
FSTL3* 1.15 (0.87-1.52) 0.33 
NT-proBNP* 1.33 (0.96-1.83) 0.09 
 
BMI, body mass index; eGFR, estimated glomerular filtration rate; GAL3, galectin-3; FSTL3, follistatin-like 
3 peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide 
*FSTL3 and NT-proBNP were log-transformed in regression models for data normalization. OR for both 
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Table S6. Logistic regression analysis for presence of obese Stage B MHD PH 
phenotype. 
 
 OR (95% CI) P value 
GAL3 
Model 1: Age and sex 1.26 (1.09-1.47) 0.003 
Model 2: Clinical risk model 1.25 (1.06-1.46) 0.007 
Model 3: Model 1 + FSTL3* + NT-proBNP*  1.33 (1.11-1.59) 0.002 
   
FSTL3* 
Model 1: Age and sex  1.03 (0.76-1.39) 0.87 
Model 2: Clinical risk model  0.92 (0.65-1.30) 0.63 
Model 3: Model 1 + GAL3 + NT-proBNP* 0.85 (0.60-1.19) 0.33 
   
NT-proBNP* 
Model 1: Age and sex  1.33 (0.96-1.84) 0.09 
Model 2: Clinical risk model 1.31 (0.93-1.84) 0.12 
Model 3: Model 1 + GAL3 + FSTL3* 1.37 (0.97-1.94) 0.08 
 
GAL3, galectin-3; FSTL3, follistatin-like 3 peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide 
Clinical risk model: history of hypertension, diabetes, hyperlipidemia, waist circumference, and estimated 
glomerular filtration rate in addition to biomarker of interest 
*FSTL3 and NT-proBNP were log-transformed in regression models for data normalization. OR for both 
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Figure S1. Correlations of diastolic function and right heart pressures and function in 








A: Mean e' and PASP relationship; B: RV/pulmonary circulation metrics and mean e' 
relationship 
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Table S1. Baseline characteristics of persons removed from Stage B MHD primary 




All obese patients 





Age, y 40  11 43  11 0.09 
Female, n (%) 60 (71) 116 (79) 0.31 
Black, n (%) 48 (56) 95 (65) 0.37 
Body mass index, kg/m2 41  11 39  8 0.09 
Diabetes 31 (36) 43 (29) 0.27 
Hypertension 44 (52) 76 (52) 0.97 
Current smoking 13 (15) 17 (11) 0.43 
Obstructive sleep apnea 17 (20) 26 (18) 0.70 
Hyperlipidemia 34 (40) 64 (44) 0.57 
Metabolic syndrome 70 (82) 107 (73) 0.12 
HDL, mg/dL 43  10 46  11 0.03 
Triglycerides, mg/dL 134 (81-186) 111 (77-173) 0.34 
eGFR, mL/min/1.73m2 135  34 124  27 0.02 
NT-proBNP, pmol/L 562 (415-701) 574 (458-729) 0.69 
GAL3, ng/mL 7  2 7  2 0.21 
FSTL3, pg/mL 5417 (4514-6471) 5721 (4477-7101) 0.26 
LVM index, g/ht2.7 43  11 41  11 0.30 
LVM/LVEDV, g/mL 1.8 (1.6-2.2) 1.9 (1.6-2.2) 0.82 
LVEF, % 63  7 65  6 0.24 
Mitral E/A ratio 1.3  0.3 1.2  0.4 0.12 
Mean e’ wave, cm/s 10  2 10  3 0.09 
E/e’ ratio 8  2 9  3 0.05 
Left atrial volume index (BSA), mL/m2 32  10 33  9 0.81 
RV basal diameter, mm 38  5 38  5 0.34 
TAPSE, mm 24  4 23  3 0.31 
PA acceleration time, ms 132  34 128  35 0.28 
PA systolic pressure, mmHg 39  12 41  13 0.28 
TAPSE/PA systolic pressure 
(mm/mmHg) 
0.61 (0.47-0.77) 0.58 (0.45-0.77) 0.34 
 
Data are mean  SD, median (interquartile range), or n (%). P value between group comparisons.  
MHD = metabolic heart disease; LV, left ventricle; LVM, left ventricular mass; LVEF, left ventricular 
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Table S2. Logistic regression analysis of predictors of obese MHD phenotype. 
 
 OR (95% CI) P value 
Age 1.11 (1.07-1.15) <0.001 
Female sex 0.29 (0.11-0.82) 0.02 
Black 1.09 (0.68-1.75) 0.73 
Hypertension 3.97 (1.93-8.19) <0.001 
Diabetes 4.98 (1.93-12.81) <0.001 
BMI 1.05 (1.00-1.10) 0.06 
Waist circumference 1.03 (1.00-1.05) 0.03 
Hyperlipidemia 3.08 (1.48-6.43) 0.003 
eGFR 0.99 (0.98-1.00) 0.19 
GAL3 1.35 (1.13-1.62) 0.001 
FSTL3* 1.30 (0.91-1.85) 0.15 
NT-proBNP* 1.36 (0.88-2.09) 0.17 
 
BMI, body mass index; eGFR, estimated glomerular filtration rate; GAL3, galectin-3; FSTL3, follistatin-like 
3 peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide 
*FSTL3 and NT-proBNP were log-transformed in regression models for data normalization. OR for both 
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Age, y 43  12 40  11 43  11 0.05 
Female, n (%) 18 (86) 99 (84) 99 (72) 0.10 
Black, n (%) 9 (43) 58 (62) 86 (62) 0.03 
Anthropometrics 
Height, m 167  6 166  11 167  9 0.54 
Ideal body weight, kg 60  6 58  11 60  9 0.41 
Actual body weight, kg 72 (64-74) 105 (87-119)* 114 (96-127)* <0.001 
Body mass index, kg/m2 25 (22-26) 36 (32-43)* 39 (34-45)* <0.001 
Body surface area, m2 1.8  0.1 2.1  0.3* 2.2  0.3* <0.001 
Waist circumference, cm 81 (74-91) 117 (102-122) 121 (107=132)*† <0.001 
Comorbidities, n (%) 
Diabetes 0 (0) 18 (19) 56 (41) <0.001 
Hypertension 0 (0) 39 (41) 82 (59) <0.001 
Current smoking 1 (4) 10 (11) 20 (14) 0.02 
Obstructive sleep apnea 0 (0) 16 (17) 27 (20) 0.04 
Hyperlipidemia 1 (5) 29 (31) 69 (50) <0.001 
Metabolic syndrome 0 (0) 58 (62) 120 (87) <0.001 
Medications, n (%) 
ACEI or ARB 0 (0) 21 (22) 59 (43) <0.001 
-Blocker 0 (0) 17 (18) 28 (20) 0.03 
Oral hypoglycemic agent 0 (0) 15 (16) 40 (29) <0.001 
Insulin 0 (0) 5 (5) 18 (13) 0.04 
Laboratory values     
Total cholesterol, mg/dL 184 (178-217) 180 (154-207) 186 (163-203) 0.36 
HDL, mg/dL 61 (52-67) 44 (38-50)* 43 (38-50)* <0.001 
Triglycerides, mg/dL 60 (48-84) 104 (74-174) 126 (82-185)* 0.003 
Triglyceride/HDL ratio 1.1 (0.7-1.6) 2.5 (1.5-3.9)* 2.9 (1.9-4.3)* 0.002 
eGFR, mL/min/1.73m2 99 (16) 125  27* 131  33* <0.001 
Biomarkers 
NT-proBNP, pmol/L 420 (279-736) 554 (415-694) 589 (373-773) 0.58 
GAL3, ng/mL 5.7  1.6 6.4  2.0 7.4  2.2*† <0.001 








Data are mean  SD, median (interquartile range), or n (%). P value reflect overall group differences. 
MHD PH-NEG, metabolic heart disease pulmonary hypertension negative individuals; MHD PH-POS, 
metabolic heart disease pulmonary hypertension positive individuals; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; HDL, high-density lipoprotein; eGFR, estimated 
glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; GAL3, galectin-3; FSTL3, 
follistatin-like 3 peptide 
*P<0.02 versus controls 
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Left heart parameters 
LV diastolic dimension, mm 45  4 47  5 46  5 0.20 
LV end-diastolic volume, mL 72 (61-80) 82 (71-104) 86 (73-105)* 0.02 
LV end-diastolic volume index, 
mL/m2 
40  9 42  10 41  9 0.77 
LV mass, g 112  24 165  47* 166  45* <0.001 
LVM index, g/ht2.7 28  6 42  11* 41  11* <0.001 
LVM/LVEDV, g/mL 1.6 (1.37-1.83) 1.9 (1.6-2.2)* 1.9 (1.6-2.2)* 0.007 
LVEF, % 64  6 65  7 63  6 0.03 
Mitral E wave, cm/s 70  13 80  17 79  18 0.16 
Mitral A wave, cm/s 53  15 61  14* 68  13* 0.001 
Mitral E/A ratio 1.4  0.4 1.4  0.4 1.2  0.3*† <0.001 
Mean e’ wave, cm/s 12  2 11  2 9  2*† <0.001 
E/e’ ratio 6  1 8  2* 9  3*† <0.001 
Left atrial diameter, mm 31  4 38  5* 38  4* <0.001 
Left atrial volume index (BSA), 
mL/m2 
32  11 33  10 32  8 0.59 
Left atrial volume index (ht), 
mL/ht2.7 
14  5 18  7* 18  5 0.08 
Right heart parameters 
RV basal diameter, mm 36  5 38  5 38  5 0.56 
TAPSE, mm 23  4 23  4 23  4 0.78 
Right atrial area, cm2 14  3 15  3 16  3 0.06 
PA acceleration time, ms 181  29 164  20 106  18*† <0.001 
PA systolic pressure, mmHg 25  6 28  5 48  8*† <0.001 










Data are mean  SD, median (interquartile range), or n (%). P value reflect overall group differences. 
MHD PH-NEG, metabolic heart disease pulmonary hypertension negative individuals; MHD PH-POS, 
metabolic heart disease pulmonary hypertension positive individuals; LV, left ventricle; LVM, left 
ventricular mass; LVEF, left ventricular ejection fraction; BSA, body surface area; ht, height; RV, right 
ventricle; TAPSE, tricuspid annular plane systolic excursion; PA, pulmonary artery 
*P<0.02 versus controls 
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Table S5. Logistic regression analysis of predictors of obese Stage B MHD PH 
phenotype. 
 
 OR (95% CI) P value 
Age 1.03 (1.01-1.05) 0.02 
Female sex 0.52 (0.27-1.00) 0.05 
Black 0.99 (0.68-1.43) 0.94 
Hypertension 2.07 (1.21-3.52) 0.008 
Diabetes 2.89 (1.56-5.34) <0.001 
BMI 1.03 (1.00-1.06) 0.07 
Waist circumference 1.02 (1.01-1.04) 0.003 
Hyperlipidemia 2.24 (1.29-3.89) 0.004 
eGFR 1.01 (1.00-1.02) 0.12 
GAL3 1.26 (1.10-1.45) 0.001 
FSTL3* 1.15 (0.87-1.52) 0.33 
NT-proBNP* 1.33 (0.96-1.83) 0.09 
 
BMI, body mass index; eGFR, estimated glomerular filtration rate; GAL3, galectin-3; FSTL3, follistatin-like 
3 peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide 
*FSTL3 and NT-proBNP were log-transformed in regression models for data normalization. OR for both 
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Table S6. Logistic regression analysis for presence of obese Stage B MHD PH 
phenotype. 
 
 OR (95% CI) P value 
GAL3 
Model 1: Age and sex 1.26 (1.09-1.47) 0.003 
Model 2: Clinical risk model 1.25 (1.06-1.46) 0.007 
Model 3: Model 1 + FSTL3* + NT-proBNP*  1.33 (1.11-1.59) 0.002 
   
FSTL3* 
Model 1: Age and sex  1.03 (0.76-1.39) 0.87 
Model 2: Clinical risk model  0.92 (0.65-1.30) 0.63 
Model 3: Model 1 + GAL3 + NT-proBNP* 0.85 (0.60-1.19) 0.33 
   
NT-proBNP* 
Model 1: Age and sex  1.33 (0.96-1.84) 0.09 
Model 2: Clinical risk model 1.31 (0.93-1.84) 0.12 
Model 3: Model 1 + GAL3 + FSTL3* 1.37 (0.97-1.94) 0.08 
 
GAL3, galectin-3; FSTL3, follistatin-like 3 peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide 
Clinical risk model: history of hypertension, diabetes, hyperlipidemia, waist circumference, and estimated 
glomerular filtration rate in addition to biomarker of interest 
*FSTL3 and NT-proBNP were log-transformed in regression models for data normalization. OR for both 
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Figure S1. Correlations of diastolic function and right heart pressures and function in 








A: Mean e' and PASP relationship; B: RV/pulmonary circulation metrics and mean e' 
relationship 
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